(CercleFinance.com) – Bayer shares are in good shape on Tuesday morning on the Frankfurt Stock Exchange, the pharmaceutical group having announced the inclusion of a first patient in an important clinical study for the future of its drug portfolio.
At 10:45 a.m., the stock increased by 0.7%, thus signing one of the strongest gains in a DAX index down 0.6%, which does not prevent it from still evolving at its lowest levels since 2012. in stock exchange.
Bayer announced today that it has enrolled the first patient in a Phase II study to evaluate the safety and effectiveness of its AB-1002 gene therapy in the treatment of heart failure.
The trial, called ‘GenePHIT’, is expected to include between 90 and 150 adults whose left ventricular ejection fraction is between 15% and 35% and who continue to suffer symptoms despite previously being treated.
The primary efficacy endpoint at 52 weeks must be based on the favorable evolution of a series of factors considered clinically significant.
AB-1002, a gene therapy still in the experimental stage, was developed by Viralgen Vector Core, a subsidiary of AskBio, the biotechnology division of Bayer.
The projects of Bayer’s pharmaceutical division are being closely monitored following the abandonment, last November, of a phase III clinical trial on a new anticoagulant, on which the market was banking heavily in order to compensate for the upcoming expiration of patents.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
